
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson has demonstrated robust operational sales growth of 11.5% in 4Q 2025, excluding the impact from generic competition affecting Stelara, indicating a strong performance in its innovative medicine division. The company’s revenue estimate for 2026 has been raised to $100.42 billion, benefiting from significant contributions from products like Tremfya, Rybrevant, and Tecvayli, reflecting positive trends in key therapeutic areas. Additionally, the stock has shown impressive performance, increasing approximately 30% since July 1, enhancing investor confidence amidst ongoing positive earnings revisions and favorable product dynamics.
Bears say
Johnson & Johnson's stock outlook is negatively impacted by the impending loss of patent exclusivity for key products, which historically leads to rapid sales declines due to competition from generics and biosimilars. Additionally, the company faces significant risks related to the disappointing launch of new products and critical pipeline data readouts, alongside macroeconomic concerns such as U.S. drug pricing reform and litigation risks from ongoing product-liability lawsuits. The recently unfavorable Daubert ruling further introduces uncertainty regarding the company's legal exposure, potentially affecting investor confidence and contributing to volatility in JNJ shares.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares